{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:16:47Z","timestamp":1778591807937,"version":"3.51.4"},"reference-count":27,"publisher":"Pleiades Publishing Ltd","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dokl Biochem Biophys"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1134\/s160767292570022x","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T19:19:09Z","timestamp":1774898349000},"page":"65-73","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Rapid Dose Escalation of Methotrexate in Rheumatoid Arthritis (Results of the Multicenter METEOR Study)"],"prefix":"10.1134","volume":"526","author":[{"given":"V. N.","family":"Amirdzhanova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Yu.","family":"Polischuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. N.","family":"Anoshenkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. B.","family":"Vinogradova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. V.","family":"Zonova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. V.","family":"Ivanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. R.","family":"Samigullina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. S.","family":"Salnikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. L.","family":"Shakhramanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. I.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. P.","family":"Yakupova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. M.","family":"Lila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. L.","family":"Nasonov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"137","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"7795_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"J.S. Smolen","year":"2023","unstructured":"Smolen, J.S., Landew\u00e9, R., Bergstra, S.A., Kerschbaumer, A., Sepriano, A., et al., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update, Ann. Rheum. Dis., 2023, vol.\u00a082, no. 1, pp. 3\u201318.","journal-title":"Ann. Rheum. Dis."},{"key":"7795_CR2","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","volume":"73","author":"L. Fraenkel","year":"2021","unstructured":"Fraenkel, L., Bathon, J.M., England, B.R., St\u00a0Clair,\u00a0E.W., Arayssi, T., et al., American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis, Arthritis Rheumatol., 2021, vol. 73, no. 7, pp.\u00a01108\u20131123.","journal-title":"Arthritis Rheumatol."},{"key":"7795_CR3","first-page":"557","volume":"54","author":"E.L. Nasonov","year":"2016","unstructured":"Nasonov, E.L., Pharmacotherapy of rheumatoid arthritis: Russian and international recommendations, Nauchno-Prakt. Revmatol., 2016, vol. 54, no. 5, pp.\u00a0557\u2013571.","journal-title":"Nauchno-Prakt. Revmatol."},{"key":"7795_CR4","first-page":"8","volume":"52","author":"E.L. Nasonov","year":"2014","unstructured":"Nasonov, E.L., Karateev, D.E., and Chichasova, N.V., New recommendations for the treatment of rheumatoid arthritis (EULAR, 2013): the place of methotrexate, Nauchno-Prakt. Revmatol., 2014, vol. 52, no. 1, pp.\u00a08\u201326.","journal-title":"Nauchno-Prakt. Revmatol."},{"key":"7795_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s41927-024-00381-y","volume":"8","author":"E. Rubio-Romero","year":"2024","unstructured":"Rubio-Romero, E., D\u00edaz-Torn\u00e9, C., Moreno-Mart\u00ednez, M., and J, D.-L., Methotrexate treatment strategies for rheumatoid arthritis: a scoping review on doses and administration routes, BMC Rheumatol., 2024, vol. 8, no. 1, p. 11.","journal-title":"BMC Rheumatol."},{"key":"7795_CR6","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1136\/annrheumdis-2014-207080","volume":"75","author":"S. Ajeganova","year":"2016","unstructured":"Ajeganova, S., van Steenbergen, H.W., van Nies,\u00a0\u00a0\u00a0J.A., Burgers, L.E., Huizinga, T.W., and van\u00a0der Helm-van Mil, A.H., Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms, Ann. Rheum. Dis., 2016, vol. 75, no. 5, pp.\u00a0867\u2013873.","journal-title":"Ann. Rheum. Dis."},{"key":"7795_CR7","first-page":"421","volume":"53","author":"E.L. Nasonov","year":"2015","unstructured":"Nasonov, E.L., Methotrexate in rheumatoid arthritis\u20132015: New facts and ideas, Nauchno-Prakt. Revmatol., 2015, vol. 53, no. 4, pp. 421\u2013433.","journal-title":"Nauchno-Prakt. Revmatol."},{"key":"7795_CR8","first-page":"435","volume":"61","author":"E.L. Nasonov","year":"2023","unstructured":"Nasonov, E.L., Amirdzhanova, V.N., Olyunin, Yu.A., Murav\u2019ev, Yu.V., Baranov, A.A., et al., Use of methotrexate in rheumatoid arthritis. Recommendations of the All-Russian Public Organization \u201cAssociation of Rheumatologists of Russia\u201d, Nauchno-Prakt. Revmatol., 2023, vol. 61, no. 4, pp. 435\u2013449.","journal-title":"Nauchno-Prakt. Revmatol."},{"key":"7795_CR9","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.semarthrit.2015.11.004","volume":"45","author":"D. Li","year":"2016","unstructured":"Li, D., Yang, Z., Kang, P., and Xie, X., Subcutaneous administration of methotrexate at high doses makes a better performance in the treatment of rheumatoid arthritis compared with oral administration of methotrexate: A systematic review and meta-analysis, Semin. Arthritis Rheum., 2016, vol. 45, no. 6, pp. 656\u2013662.","journal-title":"Semin. Arthritis Rheum."},{"key":"7795_CR10","doi-asserted-by":"crossref","unstructured":"Bujor, A.M., Janjua, S., Lavalley, M.P., Duran, J., Braun, J., and Felson, D.T., Comparison of oral versus parenteral methotrexate in the treatment of rheumatoid arthritis: A meta-analysis, PLoS One, 2019, vol. 14, no.\u00a09, p. e0221823.","DOI":"10.1371\/journal.pone.0221823"},{"key":"7795_CR11","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s11926-023-01116-7","volume":"25","author":"E. Vermeer","year":"2023","unstructured":"Vermeer, E., Hebing, R., Van De Meeberg, M.M., Lin,\u00a0M., De Meij, T., Struys, E.A., Jansen, G., Nurmohamed, M.T., \u0106alasan, M.B., and De Jonge, R., Oral versus subcutaneous methotrexate in immune-mediated inflammatory disorders: an update of the current literature, Curr. Rheumatol. Rep., 2023, vol. 25, no.\u00a012, pp. 276\u2013284.","journal-title":"Curr. Rheumatol. Rep."},{"key":"7795_CR12","unstructured":"Tamai, H., Ikeda, K., Miyamoto, T., Taguchi, H., Kuo, C.F., et al., MIRACLE Study Group, Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trial, Ann. Rheum. Dis., 2024, pp.\u00a0ard\u20132024\u2013226350."},{"key":"7795_CR13","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1111\/bcp.16158","volume":"90","author":"J.M. Tan","year":"2024","unstructured":"Tan, J.M., Upton, R.N., Foster, D.J.R., Proudman, S.M., Dhir, V., and Wiese, M.D., Pharmacokinetic-pharmacodynamic modelling and simulation of methotrexate dosing in patients with rheumatoid arthritis, Br. J. Clin. Pharmacol., 2024, vol. 90, no. 11, pp. 2763\u20132780.","journal-title":"Br. J. Clin. Pharmacol."},{"key":"7795_CR14","doi-asserted-by":"crossref","unstructured":"Hebing, R., Mahmoud, S., Lin, M., Muller, I., Heil, S., Lems, W., Nurmohamed, M., de Jonge, R., and Jansen, G., Erythrocyte methotrexate polyglutamates are substantially higher after subcutaneous methotrexate treatment in rheumatoid arthritis patients in the first months of treatment, Arthritis Rheumatol., 2021, vol.\u00a073, suppl. 9. \nhttps:\/\/acrabstracts.org\/abstract\/erythrocyte-methotrexate-polyglutamates-are-substantially-higher-after-subcutaneous-methotrexate-treatment-in-rheumatoid-arthritis-patients-in-the-first-months-of-treatment\/. Accessed December 27, 2024.","DOI":"10.1136\/annrheumdis-2021-eular.525"},{"key":"7795_CR15","first-page":"51","volume":"53","author":"E.L. Nasonov","year":"2015","unstructured":"Nasonov, E.L., New recommendations for the treatment of rheumatoid arthritis (EULAR, 2013): the place of glucocorticoids, Nauchno-Prakt. Revmatol., 2015, vol. 53, no. 5s, pp. 51\u201363.","journal-title":"Nauchno-Prakt. Revmatol."},{"key":"7795_CR16","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D. Aletaha","year":"2010","unstructured":"Aletaha, D., Neogi, T., Silman, A.J., Funovits, J., and Felson, D.T., Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative, Arthritis Rheum., 2010, vol. 62, no. 9, pp. 2569\u20132581.","journal-title":"Arthritis Rheum."},{"key":"7795_CR17","unstructured":"Syed, H.M., Tausif, A., Malab, B., Farah, I., and Talha, D., Safety profile of methotrexate therapy in patients with rheumatoid arthritis, Cureus, 2022, vol. 20, no. 14 7, p. e27047."},{"key":"7795_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/art.23144","volume":"58","author":"J. Braun","year":"2008","unstructured":"Braun, J., K\u00e4stner, P., Flaxenberg, P., W\u00e4hrisch, J., Hanke, P., et al., 6\/RH Study Group, Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial, Arthritis Rheum., 2008, vol. 58, no. 1, pp. 73\u201381.","journal-title":"Arthritis Rheum."},{"key":"7795_CR19","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.semarthrit.2015.05.003","volume":"45","author":"R. Conway","year":"2015","unstructured":"Conway, R., Low, C., Coughlan, R.J., O\u2019Donnell, M.J., and Carey, J.J., Risk of liver injury among methotrexate users: A meta-analysis of randomised controlled trials, Semin. Arthritis Rheum., 2015, vol. 45, no. 2, pp.\u00a0156\u2013162.","journal-title":"Semin. Arthritis Rheum."},{"key":"7795_CR20","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s12325-016-0295-8","volume":"33","author":"G. Bianchi","year":"2016","unstructured":"Bianchi, G., Caporali, R., Todoerti, M., and Mattana, P., Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of administration, Adv. Ther., 2016, vol. 33, no. 3, pp. 369\u2013378.","journal-title":"Adv. Ther."},{"key":"7795_CR21","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D. Aletaha","year":"2018","unstructured":"Aletaha, D. and Smolen, J.S., Diagnosis and management of rheumatoid arthritis: a review, JAMA, 2018, vol. 320, no. 13, pp. 1360\u20131372.","journal-title":"JAMA"},{"key":"7795_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s41927-019-0080-9","volume":"3","author":"W. Katchamart","year":"2019","unstructured":"Katchamart, W., Narongroeknawin, P., Chanapai, W., and Thaweeratthakul, P., Health-related quality of life in patients with rheumatoid arthritis, BMC Rheumatol., 2019, vol. 3, p. 34.","journal-title":"BMC Rheumatol."},{"key":"7795_CR23","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1002\/acr.23164","volume":"69","author":"S.A. Bergstra","year":"2017","unstructured":"Bergstra, S.A., Allaart, C.F., Stijnen, T., and Landew\u00e9, R.B.M., Meta-regression of a dose-response relationship of methotrexate in mono- and combination therapy in disease-modifying antirheumatic drug-naive early rheumatoid arthritis patients, Arthritis Care Res. (Hoboken), 2017, vol. 69, pp. 1473\u20131483.","journal-title":"Arthritis Care Res."},{"key":"7795_CR24","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.clinthera.2014.01.014","volume":"36","author":"P. Cipriani","year":"2014","unstructured":"Cipriani, P., Ruscitti, P., Carubbi, F., Liakouli, V., and Giacomelli, R., Methotrexate in rheumatoid arthritis: Optimizing therapy among different formulations. Current and emerging paradigms, Clin. Ther., 2014, vol.\u00a036, pp. 427\u2013435.","journal-title":"Clin. Ther."},{"key":"7795_CR25","doi-asserted-by":"crossref","unstructured":"Hua, C., Buttgereit, F., and Combe, B., Glucocorticoids in rheumatoid arthritis: current status and future studies, RMD Open, 2020, vol. 6, no. 1, p. e000536.","DOI":"10.1136\/rmdopen-2017-000536"},{"key":"7795_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/ard-2022-223358","volume":"82","author":"S.A. Bergstra","year":"2023","unstructured":"Bergstra, S.A., Sepriano, A., Kerschbaumer, A., Van\u00a0Der Heijde, D., Caporali, R., et al., Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis, Ann. Rheum. Dis., 2023, vol. 82, no. 1, pp. 81\u201394.","journal-title":"Ann. Rheum. Dis."},{"key":"7795_CR27","doi-asserted-by":"crossref","unstructured":"Cutolo, M., Shoenfeld, Y., Bogdanos, D.P., Gotelli, E., Salvato, M., Gunkl-T\u00f3th, L., and Nagy, G., To treat or not to treat rheumatoid arthritis with glucocorticoids? A\u00a0reheated debate, Autoimmun. Rev., 2024, vol. 23, no. 1, p. 103437.","DOI":"10.1016\/j.autrev.2023.103437"}],"container-title":["Doklady Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S160767292570022X.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1134\/S160767292570022X","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S160767292570022X.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:49:16Z","timestamp":1778590156000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1134\/S160767292570022X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7795"],"URL":"https:\/\/doi.org\/10.1134\/s160767292570022x","relation":{},"ISSN":["1607-6729","1608-3091"],"issn-type":[{"value":"1607-6729","type":"print"},{"value":"1608-3091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"20 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The work was carried out within the framework of the program of the All-Russian public organization \u201cAssociation of Rheumatologists of Russia\u201d and approved by the local ethics committee of the Nasonova Research Institute of Rheumatology (protocol no. 3 dated February 2, 2023). All procedures performed in the study involving people comply with the ethical standards of the institutional and\/or national research ethics committee and the 1964 Helsinki declaration and its subsequent amendments or comparable ethical standards. Informed voluntary consent was obtained from each participant included in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"ETHICS APPROVAL AND CONSENT TO PARTICIPATE"}},{"value":"The authors of this work declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"CONFLICT OF INTEREST"}}]}}